Hexalyse® (Tablets) Instructions for Use
Marketing Authorization Holder
Laboratoires Bouchara-Recordati (France)
ATC Code
R02AA20 (Other antiseptics)
Active Substances
Lysozyme (DCF adopted for use in France)
Biclotymol (Rec.INN registered by WHO)
Enoxolone (Rec.INN registered by WHO)
Dosage Form
| Hexalyse® | Lozenges 5 mg+5 mg+5 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
Lozenges yellow-orange in color, round, flat-cylindrical, with a bevel, with a faint characteristic odor; inclusions of orange or white color are possible.
| 1 tab. | |
| Biclotymol | 5 mg |
| Lysozyme hydrochloride | 5 mg |
| Enoxolone | 5 mg |
Excipients: lemon oil – 200 mcg, citric acid monohydrate – 10 mg, dye sunset yellow (E110) – 100 mcg, magnesium stearate – 15 mg, acacia gum – 60 mg, sucrose – up to 1200 mg.
10 pcs. – blisters (3) – cardboard packs.
Clinical-Pharmacological Group
A drug with antimicrobial and anti-inflammatory action for topical use in ENT practice and dentistry
Pharmacotherapeutic Group
Drugs for the treatment of throat diseases; antiseptics
Pharmacological Action
A combined drug for topical use with antimicrobial, antiviral, and anti-inflammatory action.
Biclotymol is an antiseptic. It is active against staphylococci, streptococci, and corynebacteria, and has a local anesthetic and anti-inflammatory effect. When applied topically, it is characterized by a prolonged action.
Lysozyme is a polypeptide mucolytic enzyme that has an antimicrobial effect. It is active against gram-positive bacteria; gram-negative microorganisms are less sensitive to lysozyme. It helps to increase the activity of the body’s non-specific defense factors, has an anti-inflammatory and mucolytic effect. Lysozyme exhibits antiviral activity (forms complexes with viruses). It belongs to the natural factors of the body’s defense.
Enoxolone is a complex triterpene isolated from glycyrrhizic acid. It inhibits 11-beta-hydroxysteroid dehydrogenase, which inactivates cortisol. It has anti-inflammatory, antimicrobial, and antiviral effects.
Pharmacokinetics
Pharmacokinetic studies of the drug Hexalyse® have not been conducted.
Indications
For the local treatment of infectious and inflammatory diseases of the mucous membrane of the oral cavity, pharynx, and larynx caused by microorganisms sensitive to biclotymol, lysozyme, and enoxolone: acute and chronic pharyngitis; pharyngolaryngitis; tonsillitis; conditions after tonsillectomy; glossitis.
ICD codes
| ICD-10 code | Indication |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04.0 | Acute laryngitis |
| J31.2 | Chronic pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37.0 | Chronic laryngitis |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| K14.0 | Glossitis |
| Z98.8 | Other specified postprocedural states |
| ICD-11 code | Indication |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05.0 | Acute laryngitis |
| CA09.2 | Chronic pharyngitis |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA03.0 | Glossitis |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| QB6Z | Surgical or postprocedural conditions, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Administer by slow dissolution in the mouth. Do not chew or swallow the lozenge whole.
For adults and children aged 6 years and older, use one lozenge.
Allow the lozenge to dissolve completely. Do not consume food or beverages for at least 15 minutes after administration.
Repeat the dose every 2 to 4 hours as needed for symptom relief.
Do not exceed 8 lozenges in a 24-hour period.
Initiate treatment at the first signs of throat discomfort or infection.
The maximum duration of treatment is 10 days. Do not use continuously for longer than 10 days.
Discontinue use and consult a physician if symptoms persist, worsen, or if high fever, headache, nausea, or vomiting occurs.
For postoperative conditions, such as after tonsillectomy, follow the specific dosage instructions provided by the surgeon.
Adverse Reactions
Possible allergic reactions, superinfection; with long-term use (more than 10 days) – oral dysbiosis with the risk of spreading bacterial and fungal infections.
Contraindications
Children under 6 years of age; hypersensitivity to the components of the combination.
Use in Pregnancy and Lactation
During pregnancy and lactation (breastfeeding), it is used only for strict indications.
Pediatric Use
Contraindication: children under 6 years of age.
Special Precautions
If within 5 days the therapeutic effect is absent or weakly expressed, the therapy used should be reconsidered.
Drug Interactions
Concomitant use of other medicinal products for topical application in the oral cavity should be avoided.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Belosalic, lotion solution for external use spray 100ml
No-spa pills 40mg, 64pcs
Arbidol, capsules 100mg, 40pcs
Noopept, pills 10mg, 50pcs
Fenotropil pills 100mg, 60pcs
Kagocel pills 12mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Mildronate capsules 500mg, 90pcs
Nootropil pills 800mg, 30pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Picamilon pills 50mg, 60pcs 